AUG 20, 2017 07:53 PM PDT
Preventing Lethal Shock During Hemorrhagic Fevers
WRITTEN BY: Kara Marker
3 3 279

The body can go into “shock” for several different reasons, but it’s never a good sign. Whatever the source of shock, the condition is lethal if left untreated (and sometimes leads to death even with treatment). From the University of Basel, researchers are looking at a common cause of shock, hemorrhagic fevers from viral infections, to find new, more effective treatments.

A transmission electron micrograph (TEM) of a number of Lassa virus virions adjacent to some cell debris. Source: CDC's Public Health Image Library

Hemorrhagic fever describes what happens to the body when multiple body organs are damaged as the body’s vascular system is breaking down. When hemorrhagic fevers lead to shock, the body’s blood pressure is so low that there is not enough oxygen in the body to prevent organ failure. Someone in shock might feel cold, anxious, and confused, or look pale with dilated pupils. Treatment options often depend on what the source of shock is (it can be from an allergic reaction, infections in the blood, a heart deficiency, or even an emotional disturbance). Oxygen, IV fluids, blood transfusion, or blood vessel-constricting drugs to direct blood flow to the heart and brain are a few options.

Lassa virus is transmitted to humans by rodents, causing a hemorrhagic fever reminiscent of the Ebola virus. This type of infection is particularly common in West Africa, and at the very last stage of the disease, people go into shock, usually leading to death. In a new study published in the journal Cell Host & Microbe, researchers use Lassa virus as a way to study what happens in the body to trigger hemorrhagic fever, with the hope of using that information to someday develop new therapies.

Interestingly, researchers identified T cells at the root of circulatory failure. T cells are a key part of the adaptive immune system, the branch that designs a specific attack against pathogenic invaders, so implicating T cells in contributing to shock was surprising.

They found that T cells “convince” so-called “scavenger” cells to mass-produce nitric oxide (NO) by releasing a substance called interferon gamma. However, NO is an antibacterial chemical; it has no power over viral infections. Instead, NO triggers blood vessel dilation, the first step toward what will eventually be circulatory failure. However, researchers already see the benefits of blocking the production of interferon gamma to prevent circulatory failure.

With a key trigger of shock identified, researchers are already moving forward on applying this knowledge in the clinic to prevent shock-related death.

Sources: LiveScience, CDC, University of Basel

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 21, 2018
Cardiology
FEB 21, 2018
How a Heart Attack Affects the Kidneys
The inflammatory response following a heart attack affects another organ too: the kidneys. From the University of Alabama at Birmingham, scientists investi
MAR 08, 2018
Immunology
MAR 08, 2018
How does brain cancer escape the immune system?
One of the most lethal forms of brain cancer owes most of its deadliness to its evasion of the immune system - a nasty trick that prevents T cells and othe
MAR 21, 2018
Health & Medicine
MAR 21, 2018
Mumps Outbreaks Are on the Rise
Getting the mumps used to be a milestone of childhood. Children would come down with them, most would recover, and that would be that. Vaccines changed all
APR 18, 2018
Health & Medicine
APR 18, 2018
Budget Cuts Mean Less Research and Care for Leprosy Patients
Leprosy isn't a disease that most people encounter. It's quite rare in the US, and there aren't many healthcare providers that are experienced
MAY 22, 2018
Cancer
MAY 22, 2018
Novel PD-L1/TGF-ß Fusion Protein for HPV-Associated Cancers Enters Phase II Clinical Trial
Novel PD-L1/TGF-ß fusion protein for HPV-associated cancers enters phase II clinical trial. Oncology researchers excited about the potential of this bi-functional protein to combat cancer
JUN 02, 2018
Immunology
JUN 02, 2018
New Test Predicts Lupus Onset
Based on several different factors, scientists have a new risk index for predicting who will develop lupus. From the Feinstein Institute for Medical Resear
Loading Comments...